Chemical Synthesis of the Anti-COVID-19 Drug Remdesivir

被引：3
|
作者：
Wang, Mo [1 ,2 ]
Zhang, Lu [2 ]
Huo, Xiaohong [1 ]
Zhang, Zhenfeng [2 ]
Zhang, Wanbin [1 ,2 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Frontiers Sci Ctr Transformat Mol, Shanghai Key Lab Mol Engn Chiral Drugs, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai, Peoples R China
来源：
CURRENT PROTOCOLS | 2021年 / 1卷 / 12期
基金：
国家重点研发计划; 中国国家自然科学基金;
关键词：
anti-COVID-19; drug; asymmetric phosphorylation; chiral bicyclic imidazole; organocatalysis; ENANTIOSELECTIVE C-ACYLATION; KINETIC RESOLUTION; GS-5734; DESIGN; EBOLA;
D O I：
10.1002/cpz1.303
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Remdesivir has become an important compound for the treatment of COVID-19. Here, we describe the catalytic asymmetric synthesis of this anti-COVID-19 drug. First, the P-racemic phosphoryl chloride is synthesized in a facile procedure. Then, it is possible to obtain the protected remdesivir via the organocatalytic asymmetric phosphorylation of protected nucleoside GS441524 with P-racemic phosphoryl chloride catalyzed by chiral bicyclic imidazole. Finally, remdesivir is easily prepared by deprotection. (c) 2021 Wiley Periodicals LLC.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir
    Wang, Mo
    Zhang, Lu
    Huo, Xiaohong
    Zhang, Zhenfeng
    Yuan, Qianjia
    Li, Panpan
    Chen, Jianzhong
    Zou, Yashi
    Wu, Zhengxing
    Zhang, Wanbin
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2020, 59 (47) : 20814 - 20819
  • [2] The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
    Chen, Jungang
    Dai, Lu
    Kendrick, Samantha
    Post, Steven R.
    Qin, Zhiqiang
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (03)
  • [3] An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
    Valipour, Mehdi
    Irannejad, Hamid
    Keyvani, Hossein
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2023, 6 (09) : 1248 - 1265
  • [4] Computational anti-COVID-19 drug design: progress and challenges
    Wang, Jinxian
    Zhang, Ying
    Nie, Wenjuan
    Luo, Yi
    Deng, Lei
    BRIEFINGS IN BIOINFORMATICS, 2022, 23 (01)
  • [5] Comparison of remdesivir and favipiravir-the anti-Covid-19 agents mimicking purine RNA constituents
    Al-Ardhi, Faiha M.
    Novotny, Ladislav
    Alhunayan, Adel
    Al-Tannak, Naser F.
    BIOMEDICAL PAPERS-OLOMOUC, 2022, 166 (01): : 12 - 20
  • [6] In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review
    Onyango, Okello Harrison
    ADVANCES IN PHARMACOLOGICAL AND PHARMACEUTICAL SCIENCES, 2023, 2023
  • [7] Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
    Mohamed El-Awady
    Heba Elmansi
    Fathalla Belal
    Rasha abo Shabana
    Journal of Fluorescence, 2022, 32 : 1941 - 1948
  • [8] The first Chinese oral anti-COVID-19 drug Azvudine launched
    Yu, Bin
    Chang, Junbiao
    INNOVATION, 2022, 3 (06):
  • [9] Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal
    El-Hachem, Nehme
    Eid, Edward
    Nemer, Georges
    Dbaibo, Ghassan
    Abbas, Ossama
    Rubeiz, Nelly
    Zeineldine, Salah
    Matar, Ghassan M.
    Bikorimana, Jean-Pierre
    Shammaa, Riam
    Haibe-Kains, Benjamin
    Kurban, Mazen
    Rafei, Moutih
    ISCIENCE, 2020, 23 (11)
  • [10] Anti-COVID-19 drug screening: Frontier concepts and core technologies
    Hua Luo
    Mingming Zhao
    Dechao Tan
    Chang Liu
    Lin Yang
    Ling Qiu
    Yan Gao
    Hua Yu
    Chinese Medicine, 15
12345